Skip to main content

Table 3 Median (range) change from baseline to week 24 in plasma biomarkers by Ctrough plasma neflamapimod levels on day 21 versus placebo

From: A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

Biomarker Placebo (N = 67) Neflamapimod by Ctrough P value for downward trend1
≤ 75% Percentile (N = 42) > 75% Percentile (N = 13)
Total tau 7.0 (−84.2, 489.2) 2.9 (−68.4, 48.4) 3.6 (−30.7, 22.8) 0.04
P-tau181 0.67 (−6.4, 44.0) 0.03 (−5.5, 6.8) 0.06 (−4.2, 3.0) 0.02
1-40 221 (−6753, 4988) 465 (−6017, 8524) 126 (−2070, 2568) 0.24
1-42 −1.6 (−150, 268) 5.5 (−298, 205) −37.7 (−136, 92) 0.05
Neurogranin 9.1 (−128, 481) −0.65(−124, 323) 11.3 (−44, 75) 0.1
Neurofilament light chain 60 (−655, 3933) 42 (−1417, 513) 53 (−322, 665) 0.16
  1. 1Jonckheere-Terpstra test for downward trend of change from baseline for 3 groups: placebo, Ctrough ≤75th percentile and Ctrough >75th percentile